The approval of Foundayo (orforglipron) by the FDA in early 2026 marked a turning point in GLP-1 medication history: for the first time, a non-peptide, oral GLP-1 receptor agonist became available specifically for chronic weight management. Until now, Ozempic (semaglutide) has dominated the GLP-1 conversation — but it's an injectable approved primarily for type 2 diabetes. How do these two medications actually compare?
This guide breaks down Foundayo vs Ozempic across every dimension: mechanism, delivery, weight loss efficacy, side effects, cost, and who each medication is best suited for.
Quick Comparison at a Glance
| Feature | Foundayo | Ozempic |
|---|---|---|
| Generic name | Orforglipron | Semaglutide |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Delivery | Daily oral tablet | Weekly subcutaneous injection |
| FDA indication | Chronic weight management | Type 2 diabetes (off-label weight loss) |
| Molecule type | Non-peptide small molecule | GLP-1 peptide analog |
| Available doses | 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, 17.2mg | 0.25mg, 0.5mg, 1mg, 2mg |
| Weight loss (ITT) | ~11.2% (17.2mg, ATTAIN-1) | ~15% (2mg, diabetes trials) |
| Self-pay cost | ~$149/mo (lowest dose); higher doses cost more | ~$935/mo list price |
| Refrigeration | No (room temp) | Yes (before first use) |
How They Work: Same Target, Different Approach
Both Foundayo and Ozempic activate the GLP-1 (glucagon-like peptide-1) receptor, which plays a central role in appetite regulation, glucose metabolism, and gastric emptying. However, they achieve this through fundamentally different molecular strategies.
Ozempic is a peptide analog — a modified version of the naturally occurring GLP-1 hormone. Its molecular structure closely mimics human GLP-1 but with modifications that dramatically extend its half-life to approximately 7 days, enabling once-weekly dosing. Because it's a peptide, it must be injected subcutaneously; oral administration would destroy it in the digestive tract (though Novo Nordisk later solved this with Rybelsus using an absorption enhancer).
Foundayo is a non-peptide small molecule — an entirely different class of compound that happens to activate the same receptor. Think of it like a different key that fits the same lock. Because it's a small molecule rather than a peptide, it survives the digestive tract intact and can be taken as a simple oral tablet. Its half-life is approximately 28 hours, requiring once-daily dosing.
This distinction matters beyond convenience. Small molecules are generally cheaper to manufacture at scale, don't require cold chain storage, and can be produced without the biological manufacturing processes that peptides demand. This is one reason Foundayo launched at a significantly lower price point.
Weight Loss Efficacy
Let's be direct about the numbers:
Foundayo (ATTAIN-1 Trial)
The pivotal ATTAIN-1 trial enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, without type 2 diabetes. Results at 72 weeks for the highest approved dose (17.2mg):
- 17.2mg dose (ITT/treatment regimen): 11.2% body weight loss (vs 2.3% placebo)
- 17.2mg dose (completers): 12.4% body weight loss
The ITT number (11.2%) is the more conservative and reliable figure, while the completers analysis (12.4%) reflects those who stayed on medication for the full trial duration. Always check which analysis type is being cited when comparing weight loss numbers across medications.
Ozempic (STEP Trials, off-label context)
Ozempic is FDA-approved for type 2 diabetes, not weight loss. However, the STEP trials (which tested semaglutide at the higher 2.4mg dose, later approved as Wegovy) showed approximately 15% weight loss. At Ozempic's maximum approved dose of 2mg, weight loss in diabetes trials was approximately 15%, though results vary depending on the population studied.
Bottom line: On raw weight loss percentage, Ozempic/semaglutide has the edge. But comparing these numbers directly requires caution — different trial populations, different durations, and different baseline characteristics can shift results significantly. For many patients, the 11.2% weight loss from Foundayo is clinically meaningful and represents the difference between a medication they'll actually take (daily pill) versus one they might skip or discontinue (weekly injection).
Side Effects Comparison
GLP-1 medications share a common side effect profile because they work on the same receptor. However, the rates differ meaningfully between Foundayo and Ozempic.
Foundayo Side Effects (ATTAIN-1)
Note: The side effect rates below are from the ATTAIN-1 trial at the 36mg trial dose, which is higher than the approved commercial doses (0.8–17.2mg). Real-world side effect rates at the approved doses may be lower.
- Nausea: 33.7% (36mg trial dose)
- Constipation: 25.4%
- Vomiting: 24.0%
- Diarrhea: 23.1%
- Decreased appetite: 9.2%
- Dyspepsia: 8.6%
- Abdominal pain: 6.1%
At the lower 6mg trial dose, nausea was 28.9% and vomiting was 13.0%, suggesting side effects are dose-dependent. Discontinuation due to adverse events was approximately 10.3% at the highest trial dose.
Ozempic Side Effects (Prescribing Information, 2mg)
- Nausea: ~20%
- Diarrhea: ~9%
- Vomiting: ~9%
- Constipation: ~5%
- Abdominal pain: ~6%
Analysis: Foundayo has notably higher rates of GI side effects, particularly nausea (33.7% vs ~20%) and constipation (25.4% vs ~5%). This is an important consideration. However, most GI side effects with GLP-1 medications are transient — they peak during dose escalation and diminish over weeks to months. The slow titration schedule for Foundayo (starting at 3mg and increasing every 4 weeks) is specifically designed to minimize these effects.
Neither medication has shown signals for serious safety concerns like pancreatitis or thyroid cancer in clinical trials at rates meaningfully different from placebo, though both carry standard GLP-1 class warnings.
Dosing and Convenience
Foundayo Dosing
- Starting dose: 0.8mg once daily
- Titrate every 4 weeks: 0.8mg → 2.5mg → 5.5mg → 9mg → 14.5mg → 17.2mg
- Take with or without food
- No water volume restrictions
- Store at room temperature
Ozempic Dosing
- Starting dose: 0.25mg once weekly for 4 weeks
- Titrate: 0.25mg → 0.5mg → 1mg → 2mg
- Subcutaneous injection (abdomen, thigh, or upper arm)
- Requires pen needles and sharps disposal
- Refrigerate before first use; room temp for up to 56 days after
Convenience winner: Foundayo. No needles, no refrigeration, no sharps containers, no injection-site reactions. For patients with needle phobia or those who travel frequently, this is a significant advantage. The daily dosing schedule might seem less convenient than weekly, but surveys consistently show most patients prefer a daily pill to a weekly injection.
Cost Comparison
Cost is where Foundayo makes its strongest case:
- Foundayo self-pay: Starting at ~$149/month for the lowest dose (0.8mg). Higher doses cost more, though Eli Lilly has not yet published the full price ladder. Eli Lilly offers a savings card bringing the cost to $25/month for commercially insured patients.
- Ozempic list price: ~$935/month. With insurance, copays vary widely ($25–$300/month depending on plan). Novo Nordisk offers savings cards for eligible patients.
- Medicare: Eli Lilly has committed to $50/month pricing for Foundayo on Medicare Part D starting July 1, 2026 (this is Lilly's own pricing commitment). Ozempic coverage under Medicare is available for the diabetes indication only — it is not covered for weight loss under the new Medicare GLP-1 Bridge program.
For uninsured or underinsured patients, Foundayo is approximately 75–85% cheaper than Ozempic at list prices. Even with insurance, Foundayo's savings card ($25/month) often beats Ozempic copays.
Who Should Choose Which?
Foundayo may be better if you:
- Prefer taking a daily pill over weekly injections
- Are paying out of pocket or have limited insurance coverage
- Want a medication specifically approved for weight loss
- Travel frequently and want room-temperature storage
- Have needle phobia
- Are on Medicare and want the $50/month pricing
Ozempic may be better if you:
- Have type 2 diabetes (Ozempic's primary indication)
- Prefer once-weekly dosing and don't mind injections
- Want potentially higher weight loss percentages
- Have good insurance coverage for Ozempic
- Have already tried and tolerated semaglutide well
- Want a medication with a longer track record
Frequently Asked Questions
Can I switch from Ozempic to Foundayo?
Yes. Since they're different molecules acting on the same receptor, no washout period is strictly required. However, timing the transition properly matters — see our detailed switching guide for step-by-step instructions.
Is Foundayo as effective as Ozempic?
Ozempic/semaglutide shows slightly higher weight loss in clinical trials (~15% vs ~11.2%). However, real-world effectiveness also depends on adherence, and many patients are more consistent with a daily pill than a weekly injection.
Do they have the same side effects?
The same types of side effects (nausea, GI issues), but at different rates. Foundayo has higher rates of nausea and constipation. Both tend to improve over time as your body adjusts.
Can I take them together?
No. Taking two GLP-1 receptor agonists simultaneously is not recommended, as it could dangerously amplify side effects without proportional benefit.
The Bottom Line
Foundayo and Ozempic represent two different approaches to GLP-1 therapy. Ozempic has the edge in raw efficacy and a longer clinical track record. Foundayo wins on convenience, cost, and accessibility. Neither is objectively "better" — the right choice depends on your individual medical situation, preferences, and budget.
The most important step is talking with your healthcare provider about which option aligns with your health goals, medical history, and practical considerations.
Sources
- Eli Lilly. ATTAIN-1 Phase 3 Trial Results. Orforglipron for Chronic Weight Management. 2025.
- Novo Nordisk. Ozempic (semaglutide) Prescribing Information. FDA.gov.
- Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." N Engl J Med. 2021;384(11):989-1002.
- FDA. Foundayo (orforglipron) Approval Letter. 2026.
- Eli Lilly. Foundayo Prescribing Information. 2026.